<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191150</url>
  </required_header>
  <id_info>
    <org_study_id>20130300</org_study_id>
    <nct_id>NCT02191150</nct_id>
  </id_info>
  <brief_title>Study of Haemodialysis Patients Switching From Aranesp to Biosimilar</brief_title>
  <acronym>SHADE</acronym>
  <official_title>Retrospective Study of Stable Haemodialysis Patients Switched From Darbepoetin Alfa to Epoetin Alfa Biosimilar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will obtain data to show insight into clinical outcomes of patients switching from
      Darbepoetin Alfa to a epoetin alfa biosimilar.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biosimilars were approved in 2007 by the EMA in EU and in 2010 by the TGA in Australia. This
      study will look at the retrospective data of patients that have switched from Darbepoetin
      Alfa to an approved epoetin alfa biosimilar. Data will be collected for the 26 week period
      prior to switch and a 26 week period post switch to a biosimilar. Data to be collected
      includes haemoglobin measurements, dose requirements, iron use, any transfusions,
      hospitalisations and other lab values including TSAT, Ferritin and albumin. Data from the
      study will be published.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Haemoglobin Concentration</measure>
    <time_frame>Duration of observation period -52 weeks</time_frame>
    <description>Mean haemoglobin concentration over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ESA Doses</measure>
    <time_frame>Duration of observation period -52 weeks</time_frame>
    <description>Doses of ESA over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose ratio</measure>
    <time_frame>Start post-switch (weeks 1-4) and pre-switch (weeks -4--1)</time_frame>
    <description>Dose ratio between the start of the post-switch observation period and pre-switch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose ratio</measure>
    <time_frame>Between end of post-switch (weeks 23-26) and pre-switch (weeks -4--1)</time_frame>
    <description>Dose ratio between the end of the post-switch observation period and pre-switch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin excursions</measure>
    <time_frame>Duration of observation period -52 weeks</time_frame>
    <description>Haemoglobin excursions (&lt;10/dL and &gt;12g/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemglobin within range</measure>
    <time_frame>Duration of observation period -52 weeks</time_frame>
    <description>Haemoglobin in the range 10-12g/dL over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSAT, ferritin and albumin values</measure>
    <time_frame>Duration of observation period -52 weeks</time_frame>
    <description>TSAT, ferritin and albumin over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron Use</measure>
    <time_frame>Duration of observation period -52 weeks</time_frame>
    <description>Iron use (dose/route) over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red cell transfusions (including number of units transfused)</measure>
    <time_frame>Duration of observation period -52 weeks</time_frame>
    <description>Red cell transfusions (including number of units transfused)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisations (including primary cause)</measure>
    <time_frame>Duration of observation period -52 weeks</time_frame>
    <description>Hospitalisations (including primary cause)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Subjects with PRCA testing and incidence of neutralizing anti-erythropoietin antibodies</measure>
    <time_frame>Duration of 52-week observation period</time_frame>
    <description>Pure Red Cell Aplasia (PRCA) test and results</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">272</enrollment>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Patients with CKD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population comprises prevalent haemodialysis (HD) patients treated at EU and
        Australian dialysis clinics after September 2008. Eligible patients will have received
        treatment with darbepoetin alfa for at least 26 weeks prior to being converted to an
        EMA/TGA-approved epoetin alfa biosimilar. At each participating study site, all potentially
        eligible patients are to be considered for enrolment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients â‰¥18 years of age

          -  Patients with CKD on haemodialysis and fulfilling the following:

               -  Received HD for at least 26 weeks prior to switching from treatment with
                  darbepoetin alfa to treatment with an EMA/TGA-approved epoetin alfa biosimilar

               -  Received darbepoetin alfa treatment i.v. for at least 26 weeks immediately prior
                  to switching to an EMA/TGA-approved epoetin alfa biosimilar (breaks due to
                  treatment being intentionally withheld are permitted)

               -  Switched from darbepoetin alfa treatment to an EMA/TGA-approved epoetin alfa
                  biosimilar at least 26 weeks prior to enrolment

               -  Received at least one dose of an EMA/TGA-approved epoetin alfa biosimilar after
                  switching from darbepoetin alfa treatment

          -  Mean monthly Hb 10-12g/dL in the 12 weeks prior to switch

          -  Stable darbepoetin alfa dose (i.e. no more than one increment or decrement of PFS) in
             the 12 weeks prior to switch

          -  Patient or patient's legally acceptable representative has provided informed consent,
             if applicable according to local requirements

        Exclusion Criteria:

          -  Treatment with an ESA other than darbepoetin alfa during the 12 weeks prior to switch
             to biosimilar

          -  More than 14 days' cumulative treatment with short-acting ESA during weeks 26-13 prior
             to switch to biosimilar

          -  Subject received chemotherapy or major surgery during the 26 weeks prior to switch to
             biosimilar

          -  Subject was enrolled in an interventional device or drug study at any time during the
             52-week data observation period or within 30 days prior to commencement of the data
             observation period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lemgo</city>
        <zip>32657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lich</city>
        <zip>35423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Egaleo, Athens</city>
        <zip>12244</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Egaleo</city>
        <zip>12242</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kallithea, Athens</city>
        <zip>17676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Larissa</city>
        <zip>41335</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patra</city>
        <zip>26225</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patra</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milazzo ME</city>
        <zip>98057</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chojnice</city>
        <zip>89-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rybnik</city>
        <zip>44-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaen</city>
        <state>AndalucÃ­a</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zamora</city>
        <state>Castilla LeÃ³n</state>
        <zip>49022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anaemia, Chronic Kidney Disease, Switching, Aranesp, Darbepoetin Alfa, Epoetin Alfa Biosimilars, Haemodialysis.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

